Veracyte, Inc.

NASDAQ:VCYT

Biotechnology

Healthcare
$25.57 +3.56%

+$1.83 today

Market cap
$2.06B
Beta
1.98
P/E (TTM)
48.0
EPS (TTM)
$1.11
52W Low $22.61High $53.66

Volume 2.45M

Average 1.05M

VCYT Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Veracyte, Inc.NASDAQ: VCYT

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin declines year over year

Q2 FY2026 selling, general & admin of $55.71M fell 1.8% year over year, ahead of the -7.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 9.6% from the prior quarter. Over 3 fiscal years it compounded at +6.6% a year.

Context

  • Selling, general & admin amounted to 40.8% of revenue in FY2025, down 5.4 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 7 analysts of $330.12M (+56.5%) for the fiscal year ending Dec 2026, a step up from the +2.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$55.71M+9.6% QoQ
Last fiscal yearDec 2025
$210.95M+2.4% YoY
LTMJun 2026
$201.58M-7.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.8%+62.1%+63.9 pp
1 year+2.4%+56.5%+54.1 pp
3-year CAGR+6.6%+22.4%+15.8 pp
5-year CAGR+19.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
210.95M USD
Year-over-year change
+2.4%
4-year CAGR
+3.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How VCYT compares with its peers on the latest reported figures

  • VCYT's LTM Jun 2026 selling, general & admin of $201.58M is the 6th highest of the 10 companies compared; the peer median is $235.6M.
  • Its year-over-year change of -7.5% is the lowest of 10, against a peer median of +22.1%.
  • Selling, general & admin amounts to 35.9% of revenue for VCYT, versus a peer median of 69.3%.
VCYT Competitors Peer median
Selling, General & Admin for VCYT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$951.07M +44.5%+15.0%74.4%
MYGNMyriad Genetics, Inc.LTM Mar 2026$537.7M -3.2%+1.5%64.9%
NEONeoGenomics, Inc.LTM Jun 2026$359.09M +0.6%+9.5%46.9%
WGSGeneDx Holdings Corp.LTM Jun 2026$292.26M +58.0%-10.9%64.3%
CSTLCastle Biosciences, Inc.LTM Mar 2026$235.6M +12.1%+17.0%69.3%
VCYTVeracyte, Inc.LTM Jun 2026$201.58M -7.5%+6.6%35.9%
BLLNBillionToOne, Inc.LTM Jun 2026$180.71M +60.0%—45.5%
BDSXBiodesix, Inc.LTM Mar 2026$91.36M +13.7%+12.5%95.1%
PSNLPersonalis, Inc.LTM Mar 2026$59.21M +26.4%-5.7%91.8%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$17.81M +22.1%-7.6%914.0%
Peer median (excluding VCYT) $235.6M+22.1%+5.5%69.3%

Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue219.51M296.54M361.05M445.76M517.15M
Cost of Revenue74.4M101.58M112.9M147.62M157.1M
Gross Profit145.11M194.95M248.15M298.15M360.05M
Gross Margin66.1%65.7%68.7%66.9%69.6%
Research & Development29.84M40.6M57.31M69.29M70.81M
Selling, General & Admin181.19M174.08M184.23M206.04M210.95M
Operating Expenses227.02M236.04M333.94M282M285.9M
Depreciation & Amortization19.59M25.93M27.19M23.46M21.42M
EBITDA(61.82M)(10.3M)(49.41M)49.21M89.62M
EBITDA Margin-28.2%-3.5%-13.7%11.0%17.3%
Operating Income(81.9M)(41.08M)(85.8M)16.14M74.15M
Operating Margin-37.3%-13.9%-23.8%3.6%14.3%
Interest Income135K1.97M7.34M11.15M0
Interest Expense241K198K15K2K0
Other Income / Expenses254K4.65M9.18M9.6M(5.95M)
Income Before Tax(81.65M)(36.43M)(76.61M)25.74M68.2M
Pre-Tax Margin-37.2%-12.3%-21.2%5.8%13.2%
Income Tax Expense(6.09M)133K(2.21M)1.61M1.85M
Net Income(75.56M)(36.56M)(74.4M)24.14M66.35M
Net Margin-34.4%-12.3%-20.6%5.4%12.8%
EPS (Basic)(1.11)(0.51)(1.02)0.320.84
EPS (Diluted)(1.11)(0.51)(1.02)0.310.82
Weighted Avg Shares67.89M71.55M72.64M76.48M78.58M
Weighted Avg Shares (Diluted)67.89M71.55M72.64M78.16M80.57M

Veracyte, Inc.

NASDAQ:VCYT

Intrinsic Alpha fair value

Locked

Current Price

$25.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.